Recent progress in drug development against COVID-19
Y XU, H LIU, J LI, J SHEN… - China Biotechnology, 2021 - manu60.magtech.com.cn
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) poses tremendous threats to public …
respiratory syndrome coronavirus 2 (SARS-CoV-2) poses tremendous threats to public …
[HTML][HTML] Drug discovery strategies for SARS-CoV-2
Coronavirus disease 2019 (COVID-19) is a novel disease caused by the severe acute
respiratory syndrome coronavirus (SARS-CoV)-2 virus that was first detected in December of …
respiratory syndrome coronavirus (SARS-CoV)-2 virus that was first detected in December of …
COVID-19 drug discovery using intensive approaches
A Asai, M Konno, M Ozaki, C Otsuka… - International journal of …, 2020 - mdpi.com
Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 …
(SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 …
COVID-19: antiviral agents, antibody development and traditional Chinese medicine
W Guan, W Lan, J Zhang, S Zhao, J Ou, X Wu, Y Yan… - Virologica Sinica, 2020 - Springer
Abstract The World Health Organization (WHO) has declared coronavirus disease 2019
(COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory …
(COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory …
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
L Dong, S Hu, J Gao - Drug discoveries & therapeutics, 2020 - jstage.jst.go.jp
The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide,
particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals …
particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals …
Current strategies of antiviral drug discovery for COVID-19
M Mei, X Tan - Frontiers in Molecular Biosciences, 2021 - frontiersin.org
SARS-CoV-2 belongs to the family of enveloped, single-strand RNA viruses known as
Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been …
Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been …
SARS-CoV-2: virology and drug repurposing approaches
R Rahmasari, H Setiawan, RR Syahdi… - Pharmaceutical …, 2020 - scholarhub.ui.ac.id
An emerging coronavirus, SARS-CoV-2, is the causative agent for the ongoing pandemic of
coronavirus disease 2019 (COVID-19), which has caused a worldwide social and economic …
coronavirus disease 2019 (COVID-19), which has caused a worldwide social and economic …
[HTML][HTML] An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
D Wang, Z Li, Y Liu - Journal of infection and public health, 2020 - Elsevier
Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease-
19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health …
19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health …
[HTML][HTML] Research and development of Chinese anti-COVID-19 drugs
The outbreak and spread of coronavirus disease 2019 (COVID-19) highlighted the
importance and urgency of the research and development of therapeutic drugs. Very early …
importance and urgency of the research and development of therapeutic drugs. Very early …
Drug Repurposing for COVID-19 and Fast Track New Drug Discovery for Emerging SARS-CoV-2 Variants
D Teli, AZ Chaudhari, D Patel… - SARS-CoV-2 Variants …, 2024 - taylorfrancis.com
COVID-19, caused by the SARS-CoV-2 virus, remains a global concern since it was first
identified in Wuhan, China in 2019. Though newly developed vaccines have already been …
identified in Wuhan, China in 2019. Though newly developed vaccines have already been …